

# Assessing risk of bias in non-randomized studies of exposures: ROBINS-E tool

Julian Higgins, University of Bristol

*...on behalf of the ROBINS-E development team, led by Julian Higgins, Rebecca Morgan, Andrew Rooney, Kyla Taylor, Kristina Thayer and Jonathan Sterne*

# ROBINS-E tool

Welcome to the website for the ROBINS-E tool (Risk Of Bias In Non-randomized Studies - of Exposures)

## Version 20 June 2023

We are pleased to make available a [full version of ROBINS-E for follow-up studies](#).

A [Word template](#) is available for completing the tool.

The tool is also available in this [ROBINS-E Excel implementation](#).

## About ROBINS-E

Observational epidemiologic studies are key to evaluation of the effects of exposures (including environmental, occupational and behavioural exposures) on human health, because evaluation through randomized controlled trials (RCTs) is not usually feasible. Even when RCTs have been conducted, the evidence that they provide may suffer from limitations. Therefore, the best evidence to guide policymakers and the public will be from observational studies that implement appropriate methods to minimize the risk of bias in their results, and from systematic reviews of such studies.

The **Risk Of Bias In Non-randomized Studies - of Exposure** (ROBINS-E) tool provides a structured approach to assessing the risk of bias in observational epidemiological studies. ROBINS-E is designed primarily for use in the context of a systematic review. It should contribute to a thorough examination of the strength of evidence about the presence of, and/or nature of, a potential effect of an exposure on an outcome. A key feature of the ROBINS-E approach is the specification, for each study, of the causal effect estimated by the result under consideration.

ROBINS-E shares many characteristics with the RoB 2 tool for randomized trials and the ROBINS-I tool for non-randomized studies of interventions, and is informing the further development of ROBINS-I. ROBINS-E includes seven domains of bias, each of which is addressed using a series of signalling questions that aim to gather important information about the study and the analysis being assessed. After the relevant signalling questions have been completed, three judgements are made:

1. The **risk of bias** in the result that arises from this domain.

# ROBINS-E: a tool to assess risk of bias in non-randomized studies – of exposures

- ROBINS-E concerns the risk of bias (RoB) in the results of a non-randomized study (observational study) that is...
  - quantitative
  - estimating the effect (harm or benefit) of an exposure
  - making comparisons of exposure groups or exposure levels

Follow-up (cohort) studies

Before/after or time series studies


Case-control studies


Cross-sectional studies


# Intervention vs exposure

*A continuum*


- Interventions
  - by a health professional
  - legislation
- Personal choices
  - type of toothbrush
  - taking a vitamin supplement
  - dietary intake
  - lifestyle, e.g. smoking, exercise
- Exposures
  - occupational
  - environmental
- Traits
  - socioeconomic status
  - biomarkers
  - genetic








## Establishing the causal effect being evaluated





- As for ROBINS-I
- We use the WN/SN (or WY/SY) construct for some questions

Yes (Y)
Probably yes (PY)
Probably no (PN)
No (N)
No information (NI)

Yes (Y)
Probably yes (PY)
<b>Weak no (WN)</b> (no, but ...)
<b>Strong no (SN)</b> (no, and ...)
No information (NI)




## ROBINS-E: risk of bias judgement

Judgement	Interpretation
<b>Low risk of bias</b>	There is little or no concern about bias with regard to this domain
<b>Some concerns</b>	There is some concern about bias with regard to this domain, although it is not clear that there is an important risk of bias
<b>High risk of bias</b>	The study has some important problems in this domain: characteristics of the study give rise to a high risk of bias
<b>Very high risk of bias</b>	The study is very problematic in this domain: characteristics of the study give rise to a very high risk of bias

Judgement	Interpretation
<b>Low risk of bias (except except for concerns about uncontrolled confounding)</b>	There is little concern about bias with regard to confounding, but risk of bias due to uncontrolled confounding cannot be excluded in an observational study

- Whether the risk of bias (arising from each domain) is sufficiently high, *in the context of its likely direction and the magnitude of the estimated exposure effect*, to **threaten conclusions** about whether the exposure has an important effect on the outcome
- Take into account
  - finding of the study (including its magnitude and the strength of evidence around it)
  - broad assessment of bias (through the likelihood of it being present, its likely direction and its likely magnitude)
- Challenging, and detailed guidance has not been developed for this
- Response options: **Yes / No / Can't tell**



- Elie Akyl, Carla Ancona, Mohammed Ansari, Bruce Armstrong, Whitney Arroyave, Nancy Berkman, Lisa Bero, Aaron Blair, Abee Boyles, Bert Brunekreef, Paul Demers, Tanja Farmer, Francesco Forastiere, Davina Gherzi, Barbara Glenn, Ali Goldstone, Gordon Guyatt, David Henry, Miguel Hernan, Julian Higgins, Judy LaKind, Juleen Lam, Ruth Lunn, Daniele Mandrioli, Joerg Meerpohl, Rebecca Morgan, Julie Obbagy, Neil Pearce, Andrew Rooney, Kenneth Rothman, Jelena Savović, Mary Schubauer-Berigan, Holger Schünemann, Pam Schwingl, Beverly Shea, Kyle Steenland, Jonathan Sterne, Patricia Stewart, Kyla Taylor, Kris Thayer, Kate Tilling, Jos Verbeek, Roel Vermeulen, Meera Viswanathan, Shelia Zahm




# Assessing risk of bias in non-randomized studies of interventions: ROBINS-I tool

Jonathan Sterne *or* Julian Higgins, University of Bristol


*...with special thanks to Miguel Hernán, Barney Reeves, Jelena Savović, Matt Page and other ROBINS-I collaborators*

- Initial development of the tool for non-randomized studies (**ROBINS-I**) was funded by the **Cochrane** Methods Innovation Fund
- Further work on **ROBINS-I** was funded by the UK **Medical Research Council** Methodology Panel (MR/M025209/1)

# ROBINS-I: development chronology







## ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

Jonathan AC Sterne,<sup>1</sup> Miguel A Hernán,<sup>2</sup> Barnaby C Reeves,<sup>3</sup> Jelena Savović,<sup>1,4</sup> Nancy D Berkman,<sup>5</sup> Meera Viswanathan,<sup>6</sup> David Henry,<sup>7</sup> Douglas G Altman,<sup>8</sup> Mohammed T Ansari,<sup>9</sup> Isabelle Boutron,<sup>10</sup> James R Carpenter,<sup>11</sup> An-Wen Chan,<sup>12</sup> Rachel Churchill,<sup>13</sup> Jonathan J Deeks,<sup>14</sup> Asbjørn Hróbjartsson,<sup>15</sup> Jamie Kirkham,<sup>16</sup> Peter Jüni,<sup>17</sup> Yoon K Loke,<sup>18</sup> Theresa D Pigott,<sup>19</sup> Craig R Ramsay,<sup>20</sup> Deborah Regidor,<sup>21</sup> Hannah R Rothstein,<sup>22</sup> Lakhbir Sandhu,<sup>23</sup> Pasqualina L Santaguida,<sup>24</sup> Holger J Schünemann,<sup>25</sup> Beverly Shea,<sup>26</sup> Ian Shrier,<sup>27</sup> Peter Tugwell,<sup>28</sup> Lucy Turner,<sup>29</sup> Jeffrey C Valentine,<sup>30</sup> Hugh Waddington,<sup>31</sup> Elizabeth Waters,<sup>32</sup> George A Wells,<sup>33</sup> Penny F Whiting,<sup>34</sup> Julian PT Higgins<sup>35</sup>



For numbered affiliations see end of article.

Correspondence to: J A C Sterne  
[jonathan.sterne@bristol.ac.uk](mailto:jonathan.sterne@bristol.ac.uk)


Additional material is published online only. To view please visit the journal online.


Cite this as: *BMJ* 2016;355:i4919  
<http://dx.doi.org/10.1136/bmj.i4919>

Non-randomised studies of the effects of interventions are critical to many areas of healthcare evaluation, but their results may be biased. It is therefore important to understand and appraise their strengths and weaknesses. We developed ROBINS-I (“Risk Of Bias In Non-randomised Studies - of Interventions”), a new tool for evaluating risk of bias in estimates of the comparative effectiveness (harm or benefit) of interventions from studies that did

such as cohort studies and case-control studies in which intervention groups are allocated during the course of usual treatment decisions, and quasi-randomised studies in which the method of allocation falls short of full randomisation. Non-randomised studies can provide evidence additional to that available from randomised trials about long term outcomes, rare events, adverse effects and populations that are typical of real world practice.<sup>1,2</sup> The availability of linked databases and compilations of electronic health records has enabled NRSI to be conducted in large representative population cohorts.<sup>3</sup> For many types of organisational or public health interventions, NRSI are the main source of evidence about the likely impact of the intervention because randomised trials are difficult or impossible to conduct on an area-wide basis. Therefore systematic reviews addressing the

# ROBINS-I: development chronology





The screenshot shows the homepage of the riskofbias.info website. The header includes a hamburger menu icon, the logo for riskofbias.info, and the text "Risk of bias tools" with a search icon. The main content area features a large dark purple banner with the text "riskofbias.info" in white. Below the banner, there is a welcome message and a list of tools. At the bottom, there is a copyright notice and contact information.

☰ **riskofbias.info** Risk of bias tools 🔍

# riskofbias.info

Welcome to our pages for risk of bias tools for use in systematic reviews.

- [RoB 2 tool \(revised tool for Risk of Bias in randomized trials\)](#)
- **NEW!** [ROB ME \(Risk Of Bias due to Missing Evidence in a synthesis\)](#)
- [ROBINS-I tool \(Risk Of Bias in Non-randomized Studies - of Interventions\)](#)
- [robvis \(visualization tool for risk of bias assessments in a systematic review\)](#)

Feedback is welcome to [risk-of-bias@bristol.ac.uk](mailto:risk-of-bias@bristol.ac.uk)

© 2021 by the authors.  
RoB 2 and ROBINS-I licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.  
Email [risk-of-bias@bristol.ac.uk](mailto:risk-of-bias@bristol.ac.uk) with feedback. (This mailbox is not monitored regularly and does not function as a help desk).

ⓘ

c.uk

- Preliminary considerations at protocol stage
  - Identify key confounding factors (& co-interventions)
- For each study:
  - Triage questions:
    - decide if a full assessment is warranted
    - determine which version of the Confounding domain to use
  - Target (idealized) randomized trial to match the study
    - PICO; effect estimate of interest (ITT vs per-protocol)
  - Examine key confounding factors (& co-interventions)
  - For each bias domain (result-level assessment)
    - Signalling questions
    - Free text descriptions
    - Risk of bias judgements, proposed by an algorithm
  - Overall risk of bias judgement (result-level assessment)
    - feed into (e.g.) GRADE

# Main changes from 2016 version

- Preliminary considerations at protocol stage
  - Identify key confounding factors (& co-interventions)
- For each study:
  - Triage questions:
    - decide if a full assessment is warranted
    - determine which version of the *Confounding* domain to use
  - Target (idealized) randomized trial to match the study
    - PICO; effect estimate of interest (ITT vs per-protocol)
  - Examine key confounding factors (& co-interventions)
  - For each bias domain (result-level assessment)
    - Signalling questions ← **Rewritten, with more issues considered**
    - Free text descriptions
    - Risk of bias judgements, **proposed by an algorithm**
  - Overall risk of bias judgement (result-level assessment)
    - feed into (e.g.) GRADE

Domain	Related terms
Bias due to confounding	<p><i>Pre- or peri-intervention</i> features, for which considerations of bias in NRSI are mainly distinct from those in RCTs</p>
Bias in classification of interventions	
Bias in selection of participants into the study	
Bias due to departures from intended interventions	<p><i>Post-intervention</i> features, for which many considerations of bias in NRSI are similar to those in RCTs</p>
Bias due to missing data	
Bias in measurement of outcomes	
Bias in selection of the reported result	

Domain	Related terms
Bias due to confounding	Versions for (a) baseline confounding only and (b) baseline and time-varying confounding
Bias in classification of interventions	New consideration of immortal time bias arising from definition of intervention groups; More specific consideration of non-differential classification bias
Bias in selection of participants into the study	New consideration of immortal time bias
Bias due to departures from intended interventions	Similar
Bias due to missing data	Much more detailed consideration of when bias arises, including consideration of (i) whether missingness depends on the true value of the outcome and (ii) imputation
Bias in measurement of outcomes	Similar
Bias in selection of the reported result	Additional consideration of analysis plans

- Core group:
  - **Jonathan Sterne, Barney Reeves, Jelena Savović, Julian Higgins**
- Wider development team and other contributors:
  - **Kate Tilling, Miguel Hernán, Alexandra McAleenan, Roy Elbers, Matthew Page, Luke McGuinness, Isabelle Boutron, Asbjørn Hróbjartsson, Ian Shrier, David Henry, Sasha Shepperd, Hugh Waddington, Su Golder, Jamie Kirkham, Doug Altman, Mohammed Ansari, Nancy Berkman, Belinda Burford, James Carpenter, Jon Deeks, Toby Lasserson, Rachel Churchill, Rebecca Armstrong, An-Wen Chan, Peter Jüni, Terri Piggott, Deborah Regidor, Hannah Rothstein, Lakho Sandhu, Lina Santaguida, Bev Shea, Jeff Valentine, Meera Viswanathan, David Moher, Yoon Loke, Elizabeth Waters, Craig Ramsay, George Wells, Vivian Welch**